MAPT and Alzheimer disease: The new framework will be able to identify subjects at risk for AD for suitable and early treatment, in particular, preclinical AD subjects (classified as A+T−(N−) or A+T+(N+)), who are not cognitively impaired but have abnormal amyloid and tau protein deposits [2].